Gastric cancer(GC) has been notorious for precision medicine due to difficulties of translational research with diverse heterogeneity. Fortunately, now we have reliable molecular subtypes of GC based on genomic data from the Cancer Genomic Atlas (TCGA), which might be useful for guiding certain ...
Precision medicine in gastric cancer: where are we now?Introduction: Despite advances in surgery, chemotherapy and radiotherapy, the overall prognosis of patients with gastric cancer remains poor. Biology driven targeted treatments could improve outcomes for this devastating disease. Areas covered: We ...
Beyond precision surgery: Molecularly motivated precision care for gastric cancer In the era of precision medicine, molecularly tailored therapeutic strategies should be individualized for cancer patients. To improve the overall clinical ... YY Choi,JH Cheong - 《European Journal of Surgical Oncology》 ...
Radiomic features derived from routine medical images show great potential for personalized medicine in gastric cancer (GC). We aimed to evaluate the current status and quality of radiomic research as well as its potential for identifying biomarkers to predict therapy response and prognosis in patients...
Gastric cancer (GC), a highly heterogeneous disease, has diverse histological and molecular subtypes. For precision medicine, well-characterized models encompassing the full spectrum of subtypes are necessary. Patient-derived tumor xenografts and organoids serve as important preclinical models in GC resear...
Precision medicine is used to treat gastrointestinal malignancies including esophageal, gastric, small bowel, colorectal, and pancreatic cancers. Cutting-edge assays to detect and treat these cancers are active areas of research and will soon become standard of care. Colorectal cancer is a prime exampl...
Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9(1):93. Google Scholar Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for...
The success of novel biomarker-driven therapies such as zolbetuximab-clzb (Vyloy) reflects an increasing shift toward precision medicine in gastric or gastroesophageal junction (GEJ) adenocarcinoma and opens new avenues for managing this notoriously difficult-to-treat cancer, according to ...
With the advent of precision medicine, the importance of gastric cancer target detection in clinical practice is increasingly prominent. At present, HER2 positivity (accounting for 10%~20%), MSI-H/dMMR (accounting for 4%~7%), and PD-L1 CPS ≥ 5 (accounting for 29%~31%) have become rout...
原著:《Oncology in the Precision MedicineEra》 译著:《精准医学时代的肿瘤学》 简介:This volume comprehensively reviews oncology in the precision medicine era of personalized care, latest developments in the field, and indications and clinical trials for the treatment of cancer with targeted therapies, ...